Most coverage pathways currently require either a type 2 diabetes diagnosis or meeting BMI criteria for the weight management indication
The introduction of semaglutide 2.4mg to the Mexican market demonstrates our dedication to providing innovative solutions for people facing this health challenge, said Valney Szuki, Vice President and General Director, Novo Nordisk Mexico
9 The following treatment options should not be considered in patients with IC/PBS because of a lack of evidence or efficacy and an increased risk of adverse effects: long-term antibiotics, intravesical instillation of resiniferatoxin or bacillus Calmette-Gurin, high-pressure hydrodistention, and long-term systemic (oral) glucocorticoid use
I would recommend this facility especially for the rehab part
In recent years, Semaglutide has also gained FDA approval for weight loss under the name Wegovy
Every patient metabolizes medication differently